A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

ClinicalTrials.gov ID: NCT07470879

Public ClinicalTrials.gov record NCT07470879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \< 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).

Study identification

NCT ID: NCT07470879
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pfizer; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Colitis, Ulcerative

Interventions

Etrasimod Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 11 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 27, 2026
Primary completion: Sep 7, 2030
Completion: Aug 17, 2034
Last update posted: Aug 23, 2026

2026 – 2034

United States locations

U.S. sites: 7
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Fink Children's Ambulatory Care Center	New York	New York	10016	Recruiting
Kimmel Pavilion - NYU Langone	New York	New York	10016	Recruiting
NYU Grossman School of Medicine	New York	New York	10016	Recruiting
NYU Langone Health (Tisch Hospital)	New York	New York	10016	Recruiting
NYU Langone Inflammatory Bowel Disease Center	New York	New York	10016	Recruiting
NYU Langone Radiology - Tisch Hospital	New York	New York	10016	Recruiting
NYU Medical Science Building (MSB)	New York	New York	10016	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07470879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 23, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07470879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →